An observational study in Lymphoma and Solid Tumor, sponsored by Vanderbilt-Ingram Cancer Center. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-25.
Sponsored by Vanderbilt-Ingram Cancer Center · Observational
RATIONALE: Studying the dendritic cells in samples of blood from patients with cancer receiving aflibercept may help doctors learn about the effect of aflibercept on dendritic cells.
PURPOSE: This laboratory study is evaluating dendritic cells in patients with advanced solid tumors or non-Hodgkin lymphoma receiving aflibercept on clinical trial VGFT-ST-0202.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Patients undergo phlebotomy and blood collection at baseline and on days 15, 29, and 57. Samples are analyzed for dendritic cell phenotype, subpopulations, maturation status, and function in terms of ability to activate autologous T cells.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 9 is below the median of 136 across 625 observational studies indexed under Lymphoma.
Browse Lymphoma studies →Vanderbilt-Ingram Cancer Center is the lead sponsor of 220 studies on the registry; 32 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Up to 25 patients; three at each dose level achieved in order to gain additional information regarding safety, pharmacokinetics, and biological effect of VEGF Trap given intravenously.
Patients with a solid tumor and is consented and eligible for enrollment onto VGFT-ST-0202. Patients who are willing to undergo phlebotomy prior to treatment, and 14 and 28 and 57 days following initial dose of VEGF-Trap. Patients with an Hgb ≥10gm at the time of blood draw.
Exclusion Criteria:
PRIOR CONCURRENT THERAPY:
immunologic technique
laboratory biomarker analysis
pharmacological study
Effect of in vivo aflibercept on the presence of different populations of dendritic cells (DC) and immature cells (ImC)
Time frame: at days 15, 29 and 64
Effect of aflibercept administration on DC function based on ability to stimulate antigen specific proliferative (allogeneic and tetanus toxoid) and cytolytic T cell responses (influenza)
Time frame: at days 15, 29 and 64
Correlation of aflibercept level with host antigen presenting cell phenotype at baseline
Time frame: at days 15, 29 and 64
No study locations are listed for this record.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt-Ingram Cancer Center